secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-006916
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure Q1 net loss narrows to $65.6M; cash $555.7M; advancing AMT-130 regulatory path
--------------------------------------------------------------------------------

- Net loss $65.6M ($1.36/sh) vs $77.2M ($1.63) in Q1 2023; revenue $8.5M vs $5.3M.
- Cash $555.7M (down from $617.9M Dec 2023); expects to fund operations into Q2 2027.
- On track for FDA interaction for AMT-130 in Q2 2024; clinical update mid-2024 with up to 3-year data on 29 patients.
- New Phase I/II trials: Fabry disease (AMT-191) enrollment begins Q2 2024; SOD1-ALS and MTLE expected Q3 2024.
- Comprehensive operational review to reduce expenses underway, completion expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/0001558370-24-006916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/qure-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer